We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EU Trial Transparency Delay Possible Due to Overwhelming Feedback: EMA
EU Trial Transparency Delay Possible Due to Overwhelming Feedback: EMA
The European Medicines Agency may postpone a trial transparency initiative that was scheduled to take effect Jan. 1, 2014, due to an overwhelming number of comments from stakeholders.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor